1
|
Chinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells. Int J Mol Sci 2019; 20:ijms20184418. [PMID: 31500366 PMCID: PMC6770323 DOI: 10.3390/ijms20184418] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 09/06/2019] [Accepted: 09/06/2019] [Indexed: 11/17/2022] Open
Abstract
Resistance to the current therapies is the main clinical challenge in the treatment of lethal metastatic prostate cancer (mPCa). Developing novel therapeutic approaches with effective regimes and minimal side effects for this fatal disease remain a priority in prostate cancer study. In the present study, we demonstrated that a traditional Chinese medicine, quality-assured Ganoderma tsugae ethanol extract (GTEE), significantly suppressed cell growth and metastatic capability and caused cell cycle arrest through decreasing expression of cyclins in mPCa cells, PC-3 and DU145 cells. GTEE also induced caspase-dependent apoptosis in mPCa cells. We further showed the potent therapeutic efficacy of GTEE by inhibiting subcutaneous PC-3 tumor growth in a xenograft model. The in vitro and in vivo efficacies on mPCa cells were due to blockade of the PI3K/Akt and MAPK/ERK signaling pathways associated with cancer cell growth, survival and apoptosis. These preclinical data provide the molecular basis for a new potential therapeutic approach toward the treatment of lethal prostate cancer progression.
Collapse
|
2
|
Masamrekh R, Kuzikov A, Veselovsky A, Toropygin I, Shkel T, Strushkevich N, Gilep A, Usanov S, Archakov A, Shumyantseva V. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors – abiraterone and galeterone – with human sterol 14α-demethylase (CYP51A1). J Inorg Biochem 2018; 186:24-33. [DOI: 10.1016/j.jinorgbio.2018.05.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 05/08/2018] [Accepted: 05/17/2018] [Indexed: 12/12/2022]
|
3
|
Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 2018; 101:211-218. [DOI: 10.1016/j.biopha.2018.02.067] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 02/19/2018] [Accepted: 02/19/2018] [Indexed: 12/29/2022] Open
|
4
|
Fernández-Cancio M, Camats N, Flück CE, Zalewski A, Dick B, Frey BM, Monné R, Torán N, Audí L, Pandey AV. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. Pharmaceuticals (Basel) 2018; 11:ph11020037. [PMID: 29710837 PMCID: PMC6027421 DOI: 10.3390/ph11020037] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 04/23/2018] [Accepted: 04/25/2018] [Indexed: 01/01/2023] Open
Abstract
The CYP17A1 gene regulates sex steroid biosynthesis in humans through 17α-hydroxylase/17,20 lyase activities and is a target of anti-prostate cancer drug abiraterone. In a 46, XY patient with female external genitalia, together with a loss of function mutation S441P, we identified a novel missense mutation V366M at the catalytic center of CYP17A1 which preferentially impaired 17,20 lyase activity. Kinetic experiments with bacterially expressed proteins revealed that V366M mutant enzyme can bind and metabolize pregnenolone to 17OH-pregnenolone, but 17OH-pregnenolone binding and conversion to dehydroepiandrosterone (DHEA) was impaired, explaining the patient’s steroid profile. Abiraterone could not bind and inhibit the 17α-hydroxylase activity of the CYP17A1-V366M mutant. Molecular dynamics (MD) simulations showed that V366M creates a “one-way valve” and suggests a mechanism for dual activities of human CYP17A1 where, after the conversion of pregnenolone to 17OH-pregnenolone, the product exits the active site and re-enters for conversion to dehydroepiandrosterone. The V366M mutant also explained the effectiveness of the anti-prostate cancer drug abiraterone as a potent inhibitor of CYP17A1 by binding tightly at the active site in the WT enzyme. The V366M is the first human mutation to be described at the active site of CYP17A1 that causes isolated 17,20 lyase deficiency. Knowledge about the specificity of CYP17A1 activities is of importance for the development of treatments for polycystic ovary syndrome and inhibitors for prostate cancer therapy.
Collapse
Affiliation(s)
- Mónica Fernández-Cancio
- Growth and Development Research Unit, Vall d'Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Núria Camats
- Growth and Development Research Unit, Vall d'Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Autonomous University of Barcelona, Barcelona 08035, Spain.
- Pediatric Endocrinology Unit, Department of Paediatrics, University Children's Hospital Bern, Bern 3010, Switzerland.
- Department of Biomedical Research, University of Bern, Bern 3010, Switzerland.
| | - Christa E Flück
- Pediatric Endocrinology Unit, Department of Paediatrics, University Children's Hospital Bern, Bern 3010, Switzerland.
- Department of Biomedical Research, University of Bern, Bern 3010, Switzerland.
| | - Adam Zalewski
- Pediatric Endocrinology Unit, Department of Paediatrics, University Children's Hospital Bern, Bern 3010, Switzerland.
- Department of Biomedical Research, University of Bern, Bern 3010, Switzerland.
| | - Bernhard Dick
- Department of Nephrology and Hypertension, University of Bern, Bern 3010, Switzerland.
| | - Brigitte M Frey
- Department of Nephrology and Hypertension, University of Bern, Bern 3010, Switzerland.
| | - Raquel Monné
- Pediatric Service, Hospital Joan XXIII, Tarragona 43005, Spain.
| | - Núria Torán
- Pathology Department, Hospital Universitari Vall d'Hebron, CIBERER, Barcelona 08035, Spain.
| | - Laura Audí
- Growth and Development Research Unit, Vall d'Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Autonomous University of Barcelona, Barcelona 08035, Spain.
| | - Amit V Pandey
- Pediatric Endocrinology Unit, Department of Paediatrics, University Children's Hospital Bern, Bern 3010, Switzerland.
- Department of Biomedical Research, University of Bern, Bern 3010, Switzerland.
| |
Collapse
|